Clinical trials: Liver Cirrhosis, active
Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers…
- Conditions
- Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH
- Trial name
- NIMBLE (NCT07122700)
- Where
- 4 sites in United States
- Volunteers
- 400 people
- Sponsor
- Foundation for the National Institutes of Health
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver…
- Trial name
- NCT07631637
- Testing
- ALN-CIDEB
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
Portal Hypertension, Chronic Liver Disease
Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement
This prospective multicentre observational reliability study will determine how much a repeated endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement differs from the first measurement in the same patient…
- Conditions
- Portal Hypertension, Chronic Liver Disease, Liver Cirrhosis
- Trial name
- REPEAT-PPG (NCT07877298)
- Testing
- Repeated EUS-Guided Portal Pressure Gradient Measurement
- Where
- 5 sites in Belgium, Canada and 2 more
- Volunteers
- 150 people
- Sponsor
- University Hospital Muenster
Liver Cirrhosis
AI-SC Multi-center Study
To examined the opportunity for Artificial Intelligence (AI) agents to evaluate transplant candidacy objectively at LT-SC, with a large language models (LLM) representing the expertise of each individual specialist (hepatologist…
- Trial name
- NCT07885007
- Testing
- evaluate the alignment between AI-SC recommendations and LT-SC decisions, Multi AI-SC model
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- University Health Network, Toronto
Primary Biliary Cholangitis (PBC)
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a…
- Trial name
- ELFIDENCE (NCT06016842)
- Testing
- Elafibranor
- Where
- 198 sites in United States, Argentina and 26 more
- Volunteers
- 276 people
- Sponsor
- Ipsen
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
The study will assess the efficacy and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
- Trial name
- NCT06419374
- Testing
- Pegozafermin
- Where
- 330 sites in United States, Argentina and 23 more
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Primary Biliary Cholangitis
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
This study will collect information from participants with Primary Biliary Cholangitis (PBC) as they use the drug elafibranor in real world setting.
- Trial name
- ELFINITY (NCT06447168)
- Where
- 72 sites in United States, Australia and 9 more
- Volunteers
- 424 people
- Sponsor
- Ipsen
Primary Biliary Cholangitis
A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
The purpose of this study is to find out about the safety and how well the study intervention (elafibranor) works in participants with PBC.
- Trial name
- ELONSEN (NCT06730061)
- Testing
- Elafibranor
- Where
- 16 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Ipsen
Pregnancy Related
Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy
The study will include participants who were exposed to at least one dose of elafibranor either within the three weeks before conception or at any time during pregnancy (based on estimated last menstrual period [LMP]).
- Trial name
- NCT07556913
- Testing
- Elafibranor
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Ipsen
Chronic Liver Disease and Cirrhosis, Liver Cancer
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.
- Conditions
- Chronic Liver Disease and Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- LivMOD (NCT04690972)
- Testing
- Blood sample during surgery, Taking an additional biopsy, Blood sample during diagnostic test
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity.
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Trial name
- OPTIMAL (NCT07058155)
- Testing
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cleveland Clinic
End-stage Liver Disease (ESLD), Acute Liver Failure
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given…
- Conditions
- End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
- Trial name
- REFRAME-MP (NCT07585890)
- Testing
- Endischemic hypothermic oxygenated machine perfusion (any device), Endischemic (back-to-base) normothermic machine perfusion (any device), Continuous (device-to-donor) normothermic machine perfusion (any device)
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 10,000 people
- Sponsor
- University Medical Center Groningen
Alcoholic Liver Disease (ALD), Alcohol Use Disorder
Elastography-based Brief Alcohol Intervention in Hospitalized Individuals
Harmful alcohol use is a common cause of hospital admissions and the leading cause of liver cirrhosis. Timely detection of liver disease is crucial to prevent liver disease progression and reduce alcohol-related harms.
- Trial name
- PREDILECTION (NCT07637539)
- Testing
- Elastography-based brief alcohol intervention
- Where
- 8 sites in Norway
- Volunteers
- 500 people
- Sponsor
- Oslo University Hospital
Heart Failure, Liver Fibrosis
Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
Magnetic resonance elastography is a novel non-invasive MRI technique to obtain stiffness of soft tissues such as liver, heart, kidneys, etc.
- Conditions
- Heart Failure, Liver Fibrosis, Cardiac Transplant Rejection, Aortic Aneurysms
- Trial name
- MRE (NCT01757730)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Arunark Kolipaka
Primary Biliary Cirrhosis
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver…
- Trial name
- ELATIVE (NCT04526665)
- Testing
- Elafibranor 80mg
- Where
- 115 sites in United States, Argentina and 12 more
- Volunteers
- 161 people
- Sponsor
- Ipsen
Hepatitis B
Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia
The goal of this observational study is to study models of care for decentralized hepatitis B treatment in Ethiopia. Three different models of decentralized HBV care (standard model, simplified model, test-and-treat model) will…
- Trial name
- NCT06586983
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- Ethiopia
- Volunteers
- 4,500 people
- Sponsor
- Oslo University Hospital
Cirrhosis, Advanced Chronic Liver Disease
Natural History of Advanced Chronic Liver Diseases
This is a retrospective-prospective registry cohort study. Patients with advanced chronic liver disease (ACLD) will be prospectively invited to this study. The study follow-up duration will be 10 years.
- Trial name
- NCT07042308
- Testing
- Transient elastography
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Liver Fibrosis, Portal Hypertension
- Trial name
- ENDO-MASH (NCT07877272)
- Testing
- Non-invasive MASLD and portal hypertension assessment, Single-session endohepatology assessment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Muenster
Sexual Dysfunction in Patients With Cirrhosis Awaiting Liver Transplantation
Sexual Dysfunction in Cirrhosis
The prevalence of erectile dysfunction (ED) is about 10% in the general population, but increases with age, ranging from 9.1% in men 40-49 years to 55% in men >70.
- Trial name
- SEDYC (NCT05428267)
- Testing
- questionnaire, blood collection
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Fibrosis, Hepatic Cirrhosis
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
- Trial name
- BRAVO (NCT07610837)
- Testing
- AZD2389
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 104 people
- Sponsor
- AstraZeneca